RE:My ScenarioHi Nikma97,
I'm having some trouble understanding your 'My Scenario'. Can you clarify some points for me?
If there is a reverse split of ten to one in the first quarter of 2019, how can the share price be $1.00-$1.20? You have it at $1.20 at the end of 2018 Q4. Are you suggesting a beat down from $12.00 to $1.20 or less?
You seem to acknowlege Ryplazim and IVIG approval as those they are relatively insignificant events. Why do you not mention the accompanying revenues in your bullet point? For a company who's share price is where it is at due to an almost obsessive focus on the balance sheet, wouldn't this be relavent in your scenario?
What big deal with a big pharma are you referring to? IPF or another indication related to heart, liver or kidney. Or do you think PLI will give all of these indications to one company?
Thanks,
Felco